|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1996-9-11
|
|
pubmed:abstractText |
Forty-two patients with relapsed or refractory Hodgkin's disease (HD) were treated with high-dose chemotherapy (BEAM regimen) followed by autologous bone marrow and/or peripheral blood progenitor cell (PBPC) rescue. There was one procedure-related death and the overall response rate at 6 months was 88% (95% confidence interval 78-98%). The 2 year overall and event-free survival was 81% (95% confidence interval 65-96%) and 74% (95% confidence interval 58-89%) respectively. Median follow-up was 33 months. The use of PBPC instead of marrow resulted in a significant shortening of the time to engraftment (P < 0.01). Multivariate analysis identified the pre-transplant LDH level as a highly significant factor in predicting overall survival (P = 0.007). The BEAM regimen is an effective conditioning schedule that is well tolerated but patients with a raised LDH at the time of transplant remain at high risk of early relapse and death due to disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
383-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8704691-Adolescent,
pubmed-meshheading:8704691-Adult,
pubmed-meshheading:8704691-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8704691-Bone Marrow Transplantation,
pubmed-meshheading:8704691-Carmustine,
pubmed-meshheading:8704691-Combined Modality Therapy,
pubmed-meshheading:8704691-Cytarabine,
pubmed-meshheading:8704691-Female,
pubmed-meshheading:8704691-Follow-Up Studies,
pubmed-meshheading:8704691-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:8704691-Hodgkin Disease,
pubmed-meshheading:8704691-Humans,
pubmed-meshheading:8704691-L-Lactate Dehydrogenase,
pubmed-meshheading:8704691-Male,
pubmed-meshheading:8704691-Melphalan,
pubmed-meshheading:8704691-Middle Aged,
pubmed-meshheading:8704691-Podophyllotoxin,
pubmed-meshheading:8704691-Prognosis,
pubmed-meshheading:8704691-Recurrence,
pubmed-meshheading:8704691-Survival Rate,
pubmed-meshheading:8704691-Transplantation, Autologous,
pubmed-meshheading:8704691-Treatment Outcome
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease.
|
|
pubmed:affiliation |
Birmingham Heartlands Hospital, Bordesley Green East, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|
